| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Quoin Pharmaceuticals, Ltd. (QNRX) has 4 insiders with recent SEC Form 4 filings, including 18 buys and 1 sell. QNRX is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| Dir | 15.2K | $70.5K | - | |
| Dir | 13.7K | $63.6K | - | |
| CFO | 10.3K | $48.0K | - | |
| Dir | 4.1K | $19.1K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Oct 14, 2025 | Langer Dennis63 | Director | Buy | 15,152 | $8.49 | $128,640.48 | +1,515,200% | -16.6% | - | |
| Dec 23, 2024 | Carter Denise P. | Chief Operating Officer | Buy | 555,556 | $0.45 | $250,000.20 | +1,180% | -43.3% | -26.9% | |
| Dec 23, 2024 | Myers Michael | Chief Executive Officer | Buy | 555,556 | $0.45 | $250,000.20 | +1,176% | -43.3% | -26.9% | |
| Dec 23, 2024 | Culverwell Anthony James | Director | Buy | 100,000 | $0.45 | $45,000.00 | +31,546% | -43.3% | -26.9% | |
| Dec 23, 2024 | Dunn Gordon | Chief Financial Officer | Buy | 122,221 | $0.45 | $54,999.45 | +423.6% | -43.3% | -26.9% | |
| Sep 10, 2024 | Dunn Gordon | Chief Financial Officer | Buy | 28,856 | $0.80 | $23,204.80 | +86.3% | +12.1% | -69.6% | |
| Sep 4, 2024 | Carter Denise P. | Chief Operating Officer | Buy | 37,735 | $0.76 | $28,737.13 | +63.0% | +2.4% | -72.8% | |
| Sep 4, 2024 | Myers Michael | Chief Executive Officer | Buy | 37,894 | $0.76 | $28,916.10 | +64.6% | +2.4% | -72.8% | |
| Jun 7, 2024 | Langer Dennis63 | Director | Sell | 297 | $0.73 | $217.40 | -84.9% | +10.7% | -65.0% |